Head of Immuno-Oncology Research and Translation
Dr. Jon Terrett
Dr. Jon Terrett has an extensive track record of discovering and progressing immuno-oncology drug candidates into the clinic. Prior to joining our company, Jon served as the Vice President of Oncology Discovery for CytomX, an oncology-focused biotechnology company focused on developing a novel class of antibody therapeutics. In addition, Jon has held various R&D leadership roles in biopharma, including serving as the Chief Scientific Officer at Oxford Biotherapeutics, and as a director at various biotechnology companies including Medarex, CellTech and Oxford Glycosciences. Jon received a Ph.D. in genetics at the University of Nottingham and a B.S. in genetics at the University of Sheffield.
You are now leaving the CRISPR Therapeutics website.
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.